|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf210 |
Gene summary for C1ORF210 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf210 | Gene ID | 149466 |
| Gene name | chromosome 1 open reading frame 210 | |
| Gene Alias | TEMP | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IVY1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149466 | C1orf210 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.79e-12 | 4.07e-01 | -0.1808 |
| 149466 | C1orf210 | HTA11_78_2000001011 | Human | Colorectum | AD | 6.38e-03 | 2.24e-01 | -0.1088 |
| 149466 | C1orf210 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.73e-16 | 4.43e-01 | -0.1954 |
| 149466 | C1orf210 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.43e-07 | 9.03e-01 | -0.2602 |
| 149466 | C1orf210 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.37e-03 | 4.55e-01 | -0.2196 |
| 149466 | C1orf210 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.68e-14 | 3.19e-01 | -0.1464 |
| 149466 | C1orf210 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.20e-03 | 1.19e-01 | -0.1001 |
| 149466 | C1orf210 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.39e-04 | 2.06e-01 | -0.059 |
| 149466 | C1orf210 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.40e-06 | 4.71e-01 | -0.2061 |
| 149466 | C1orf210 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.43e-02 | 2.35e-01 | -0.0842 |
| 149466 | C1orf210 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.47e-02 | 1.63e-01 | 0.096 |
| 149466 | C1orf210 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.30e-03 | 3.82e-01 | 0.0131 |
| 149466 | C1orf210 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.53e-04 | 1.96e-01 | 0.3859 |
| 149466 | C1orf210 | LZE5T | Human | Esophagus | ESCC | 1.29e-02 | 2.46e-01 | 0.0514 |
| 149466 | C1orf210 | LZE24T | Human | Esophagus | ESCC | 3.63e-07 | 3.02e-01 | 0.0596 |
| 149466 | C1orf210 | P1T-E | Human | Esophagus | ESCC | 2.91e-02 | 1.70e-01 | 0.0875 |
| 149466 | C1orf210 | P2T-E | Human | Esophagus | ESCC | 4.04e-09 | 1.03e-01 | 0.1177 |
| 149466 | C1orf210 | P4T-E | Human | Esophagus | ESCC | 2.20e-07 | 1.89e-01 | 0.1323 |
| 149466 | C1orf210 | P5T-E | Human | Esophagus | ESCC | 2.17e-04 | 8.31e-02 | 0.1327 |
| 149466 | C1orf210 | P8T-E | Human | Esophagus | ESCC | 1.70e-10 | 1.82e-01 | 0.0889 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf210 | SNV | Missense_Mutation | c.58N>C | p.Val20Leu | p.V20L | Q8IVY1 | protein_coding | tolerated(0.11) | benign(0) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| C1orf210 | SNV | Missense_Mutation | c.200G>A | p.Arg67His | p.R67H | Q8IVY1 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
| C1orf210 | SNV | Missense_Mutation | rs768886063 | c.44N>T | p.Pro15Leu | p.P15L | Q8IVY1 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C1orf210 | SNV | Missense_Mutation | rs756081725 | c.271G>A | p.Glu91Lys | p.E91K | Q8IVY1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| C1orf210 | SNV | Missense_Mutation | novel | c.238N>T | p.Val80Leu | p.V80L | Q8IVY1 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| C1orf210 | SNV | Missense_Mutation | novel | c.37N>A | p.Glu13Lys | p.E13K | Q8IVY1 | protein_coding | tolerated(0.12) | benign(0.059) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C1orf210 | SNV | Missense_Mutation | c.324G>C | p.Arg108Ser | p.R108S | Q8IVY1 | protein_coding | deleterious(0) | possibly_damaging(0.845) | TCGA-MN-A4N1-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C1orf210 | SNV | Missense_Mutation | novel | c.139N>T | p.Leu47Phe | p.L47F | Q8IVY1 | protein_coding | tolerated(0.07) | probably_damaging(0.939) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1orf210 | SNV | Missense_Mutation | novel | c.137N>G | p.Leu46Arg | p.L46R | Q8IVY1 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1orf210 | SNV | Missense_Mutation | c.200N>A | p.Arg67His | p.R67H | Q8IVY1 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |